Genetron Holdings Ltd Revenue Growth Rates (GTH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Genetron Holdings Ltd  (NASDAQ: GTH)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

GTH's Revenue Growth by Quarter and Year

Genetron Holdings Ltd's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GTH Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December 94.34
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 94.34





GTH Revenue fourth quarter 2022 Y/Y Growth Comment
Genetron Holdings Ltd reported Revenue increase of 13.01% year on year in the fourth quarter 2022, to $ 94.34 millions, this is lower than Genetron Holdings Ltd's recent average Revenue improvement of 20.67%.

Looking into fourth quarter 2022 results within Medical Laboratories industry 15 other companies have achieved higher Revenue growth. While Genetron Holdings Ltd' s Revenue growth of 13.01% ranks overall at the positon no. 1684 in the fourth quarter 2022.


GTH Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December 13.01 % 28.31 % - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   13.01 % 28.31 % - -

Financial Statements
Genetron Holdings Ltd's fourth quarter 2022 Revenue $ 94.34 millions GTH's Income Statement
Genetron Holdings Ltd's fourth quarter 2021 Revenue $ 83.48 millions Quarterly GTH's Income Statement


GTH Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   13.01 % 28.31 % - -


Back to GTH Growth rate Comparisons >> Back to GTH Growth rate Comparisons >>


Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #16
Healthcare Sector #272
Overall #1684

Revenue Y/Y Growth Statistics
High Average Low
28.31 % 20.67 % 13.02 %
(Dec 31 2021)   (Dec 31 2022)
Revenue fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #16
Healthcare Sector #272
Overall #1684
Revenue Y/Y Growth Statistics
High Average Low
28.31 % 20.67 % 13.02 %
(Dec 31 2021)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Genetron Holdings Ltd's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GTH's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GTH's IV. Quarter Q/Q Revenue Comment


Genetron Holdings Ltd's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 94.34 $ 83.48 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 13.02 % 28.31 % - - -
Year on Year Revenue Growth Overall Ranking # 1026 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 13.02 % 28.31 % - - -
Seq. Revenue Growth (TTM) Overall Ranking # 1021 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2022 period, Genetron Holdings Ltd's cumulative twelve months Revenue were $ 94 millions, company would post below average annual Revenue growth of 28.31% year on year, if the fiscal year would end at Dec 31 2022.
A slow-down in the Genetron Holdings Ltd's Revenue growth from the 0% growth in Dec 31 2021.

In the Healthcare sector 167 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1026.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 7
Healthcare Sector # 168
Overall # 1026

Revenue TTM Y/Y Growth Statistics
High Average Low
28.31 %
 20.67 %
13.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 168
S&P 500 # 1021
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2022 period, Genetron Holdings Ltd's cumulative twelve months Revenue were $ 94 millions, company would post below average annual Revenue growth of 13.02% year on year, if the fiscal year would end at Dec 31 2022.
A slow-down in the Genetron Holdings Ltd's Revenue growth from the 0% growth in Dec 31 2021.

In the Healthcare sector 167 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1026.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 7
Healthcare Sector # 168
Overall # 1026

Revenue TTM Y/Y Growth Statistics
High Average Low
28.31 %
20.67 %
13.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 168
S&P 500 # 1021




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GTH's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2022
Maxcyte inc 22.38%$ 22.376 millions
Esperion Therapeutics Inc 22.19%$ 22.187 millions
Evotec Se21.59%$ 21.587 millions
Charles River Laboratories International inc 21.52%$ 21.523 millions
Aurinia Pharmaceuticals Inc 21.50%$ 21.496 millions
Neuronetics Inc 21.14%$ 21.142 millions
Zynex inc 20.90%$ 20.903 millions
Clearpoint Neuro Inc 20.83%$ 20.831 millions
Lifestance Health Group Inc 20.72%$ 20.719 millions
Paragon 28 inc 20.42%$ 20.416 millions
Infinity Pharmaceuticals Inc 20.40%$ 20.399 millions
Atricure Inc 20.23%$ 20.227 millions
Insulet Corporation20.15%$ 20.149 millions
Hutchmed china Limited19.73%$ 19.735 millions
Tactile Systems Technology Inc 19.72%$ 19.719 millions
Semler Scientific inc 19.52%$ 19.520 millions
Biomarin Pharmaceutical Inc19.50%$ 19.503 millions
Thorne Healthtech Inc 19.48%$ 19.480 millions
Cadre Holdings inc 19.42%$ 19.421 millions
Sorrento Therapeutics Inc 19.26%$ 19.257 millions
Veracyte Inc 19.25%$ 19.248 millions
1life Healthcare Inc 19.12%$ 19.123 millions
Integer Holdings Corporation18.98%$ 18.979 millions
Biolife Solutions Inc 18.64%$ 18.641 millions
Puma Biotechnology Inc 18.64%$ 18.639 millions
Astrazeneca Plc18.53%$ 18.532 millions
United Therapeutics Corporation18.38%$ 18.377 millions
23andme Holding Co17.66%$ 17.664 millions
Clene Inc 17.59%$ 17.588 millions
Guardant Health Inc 17.37%$ 17.374 millions


About Genetron Holdings Ltd Revenue Growth Rates (GTH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Genetron Holdings Ltd (CIK 1782594).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-23-059794
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Genetron Holdings Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.